Navigation Links
ReSeeVit Slit Lamp System

ProductsReSeeVit Slit Lamp System
Company Veatch Ophthalmic Instruments
Item ReSeeVit Slit Lamp System
Features 
  • Capable of accepting up to 2 RGB, 1 composite and 1 S-video inputs in NTSC or PAL format.
  • Targa 24, Targa 16. PSD adobe, RAS Sun Microsystems, BMP Microsoft, PCX Z Soft Corp., PCT Macintosh color and Jpeg formats supported.
  • Utilizes a powerful patient database system capable of managing up to 640 gigabytes of data.
  • Ability to send images via modem or over the Internet.
  • Ability to accept any scanned in document and add the document to the database
  • Video camera resolution 768 X 494, image capture board 640 X 480 and monitor is 800 X 600.
    • Description The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes the 5V slit Lamp for optimal performance.
    Info Veatch Ophthalmic Instruments
    Customer Service: (800) 447-7511
    Web site: http://www.veatchinstruments.com/

    Related medicine products :

    1. ReSeeVit 5V
    2. ReSeeVit 5Z
    3. ReSeeVit 3Z
    4. ReSeeVit CR-DGi Digital Imaging Sys Cmp
    5. Silicone Oil Cannula System - 20 Gauge
    6. Silicone Oil Cannula System - 19 Gauge
    7. SuperVu Galilean System
    8. KOWA nonmyd 7 / VK-2 Digital Imaging System
    9. KOWA nonmyd a-D / VK-2 Digital Imaging System
    10. Refraction System RT-2100
    11. Odyssey Phacoemulsification System
    Measure SpO2 and tcpCO2 with a single sensor.
    The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)
    Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2.
    ...versity is the only online source of nationally ac...sts, critical care nurses and other healthcare pro...re available online 24/7, so you can take them at ... and a certificate is issued upon course completio...
    Medicine Products:
    (Date:12/2/2008)...swire/ -- Today, the University HealthSystem,Cons... has been appointed Vice,President, Quality and P...ing,a year and a half as director of quality and ...al in Chicago, Ill. Previously, she was the senio...area. , "Julie,s experience at Northwestern...
    (Date:12/2/2008)...ec. 1 diaDexus, Inc. today,announ...mated format of the,PLAC Test for Lp-PLA2. This a...unning on a wide range of clinical chemistry analy...g Administration (FDA) in December 2007. diaDexus ...d PLAC Test to Europe. , The PLAC Test is t...
    (Date:12/2/2008)...onash University, The Brigham and Women,s Hospital...ceuticals has found a new drug with the potential ... shift work. , Dr Shantha Rajaratnam from Monas...d Psychological Medicine said tasimelteon, a drug ...uld be a highly effective treatment for circadian ...
    (Date:12/2/2008)...for an Injunction in Federal Court to Reclaim Over...ewswire-USNewswire/ -- Registered nurses for River...al Medical Center, filed a Fair Labor Standards Ac...day to stop the county from violating federal law ...ho are seeking to represent all 867 registered nur...
    Breaking Medicine News(10 mins):Health News:Julie Cerese Returns to University HealthSystem Consortium as Vice President of Quality and Patient Safety 2Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:New medication brings hope of jet lag cure 2Health News:Riverside County Registered Nurses File a Lawsuit to Stop County's Violation of Federal Law 2
    ...Netherlands the effects of multiple sclerosis (MS)...ger portions of the brain, which seemingly appear ... Vrenken, Ph.D., from the Multiple Sclerosis Cente...msterdam, who have published their findings that i...
    ...ry medicine cabinet, may help in easing out prosta...yo Clinic.// Aspirin is known to help in the prev...strokes and several types of cancer along with hea...t may help solve some of the urinary problem thoug...
    ...te of the University of Sao Paulo Medical School i... advice was the key to// getting the best care in ...ndings of the study to be published in the Septemb...can College of Cardiology showed that patients ass...
    ...laming GOP lawmakers for not seeking lower prices ...n launched by the// Association of Trial Lawyers o...e lawmakers for blocking provisions that would hav... drug companies for the best prescription cost has...
    Other Medicine News:Health News:Damage Due to MS Might Extend Into Larger Portions Of The Normal Brain 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2
    (Date:12/2/2008)...CHICAGO, Dec. 3 Breast-... detection of cancers not found on mammograms or b...oday at the annual meeting of,the Radiological So...identify the most difficult to detect breast cance...achel F. Brem, M.D., professor of,radiology and d...
    (Date:12/2/2008)...SKOKIE, Ill., Dec. 2 Horizon Thera... company, today announced that two pivotal,Phase ...ct candidate, HZT-501,met all primary endpoints....tion product containing ibuprofen and famotidine, ...n in the incidence of non-steroidal,anti-inflamma...
    (Date:12/1/2008)...ROCKVILLE, Md., Dec. 1 V...s publication in The Lancet , one of the world,s ...ls of its novel circadian regulator, experimental ...y Rajaratnam et al(1) is entitled "Melatonin agoni...ter sleep-time shift: two randomised controlled mu...
    (Date:12/1/2008)...Baby Girl with Hypophosphatasia Treated With ENB-0... in Winnipeg , , MONTREAL, Dec. 1 /PRNewswi... company focused on developing novel therapeutics ...he first infant patient in its clinical program fo...ing Enzyme Replacement Therapy (ERT) with ENB-0040...
    Breaking Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 1Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 1VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 3VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 4VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 5VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 6Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 1Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 2Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 3Chemo May Limit Fertility in Breast Cancer Survivors 20748 1Chemo May Limit Fertility in Breast Cancer Survivors 20748 2
    ...ontinue Phase II Profiling,in Diabetic Patients ,...ne 2007-Speedel,(SWX: SPPN) today announced that i... development of its family of renin inhibitors wit...f-concept clinical,trial with SPP635 for the treat...lts, the company is to continue developing SPP635 ...
    ...(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmace...cals, a division of Wyeth (NYSE: WYE), today annou...l extension study of,subcutaneous methylnaltrexone...(OIC) in patients with advanced illness. The resul...nal Association of,Supportive Care in Cancer (MASC...
    Other Medicine Technology:Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 2Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 3Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 4Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 5Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 6Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 7Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 8Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6